| scholarly article | Q13442814 |
| P2093 | author name string | Paul Grootendorst | |
| P433 | issue | 2 | |
| P304 | page(s) | 79-99 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Canadian Journal of Clinical Pharmacology | Q15766787 |
| P1476 | title | Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment | |
| P478 | volume | 9 |
| Q37113030 | Assurance-médicaments nationale: Le moment d'aller de l'avant |
| Q36196926 | Canadian pharmacare: looking back, looking forward |
| Q34977603 | Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. |
| Q33701810 | Cost shifting and timeliness of drug formulary decisions in atlantic Canada. |
| Q37103248 | Does Equity in Healthcare Use Vary across Canadian Provinces? |
| Q34064267 | Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data |
| Q36876028 | Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand |
| Q91625235 | Medication Reimbursement Model and Cost Savings in a Canadian Ambulatory Hemodialysis Program |
| Q37112999 | National pharmacare: Time to move forward |
| Q59133098 | Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare |
| Q34132615 | Prescription drug coverage: an essential service or a fringe benefit? |
| Q36978229 | Public drug plan coverage for children across Canada: a portrait of too many colours |
| Q84628674 | Re: "cost shifting and timeliness of drug formulary recommendations in atlantic canada," healthcare policy, vol. 5, no. 3, 2010 |
| Q43527824 | Resident physician and hospital pharmacist familiarity with patient discharge medication costs |
| Q36179271 | Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010 |
| Q36978778 | The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada |
| Q34161152 | The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy. |
| Q28069734 | Universal prescription drug coverage in Canada: Long-promised yet undelivered |
Search more.